Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
25.3 ^USD	+31.43%		+61.56%	+148.28%

Apr. 16	Transcript : Cullinan Oncology, Inc. - Special Call
Apr. 16	Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases	CI

Cullinan Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 14, 2024 at 07:22 am EDT

Cullinan Oncology, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 153.16 million compared to net income of USD 111.21 million a year ago. Basic loss per share from continuing operations was USD 3.69 compared to basic earnings per share from continuing operations of USD 2.46 a year ago.

Diluted loss per share from continuing operations was USD 3.69 compared to diluted earnings per share from continuing operations of USD 2.38 a year ago.

Latest news about Cullinan Therapeutics, Inc.

Transcript : Cullinan Oncology, Inc. - Special Call	Apr. 16
Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases	Apr. 16	CI
Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding from a group of investors	Apr. 14	CI
Cullinan Oncology, Inc.(NasdaqGS:CGEM) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave	Mar. 14	MT
Cullinan Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024	Mar. 14	CI
Cullinan Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Cullinan Oncology Secures FDA Approval for CLN-619's Investigational New Drug Application in Multiple Myeloma	Mar. 01	MT
Cullinan Oncology Insider Sold Shares Worth $647,200, According to a Recent SEC Filing	Feb. 05	MT
Cullinan Oncology Insider Sold Shares Worth $563,600, According to a Recent SEC Filing	Jan. 31	MT
Transcript : Cullinan Oncology, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM	Jan. 11
Cullinan Oncology Doses First Patient in Study of Advanced Solid Tumor Treatment Candidate	Dec. 15	MT
Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines	Dec. 14	CI
Cullinan Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023	Nov. 03	CI
Transcript : Cullinan Oncology, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 10:50 AM	23-09-13
Cullinan Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial	23-08-03	CI
Cullinan Oncology, Inc.(NasdaqGS:CGEM) added to Russell 2000 Value-Defensive Index	23-06-23	CI
Cullinan Oncology, Inc.(NasdaqGS:CGEM) added to Russell 2000 Defensive Index	23-06-23	CI
Cullinan Oncology, Inc. Announces Transition of Patrick Baeuerle from Chief Scientific Officer of the Company to Co-Founder, Chief Scientific Advisor, Chair of Scientific Advisory Board	23-06-14	CI
Insider Sell: Cullinan Oncology	23-06-08	MT
Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors	23-05-25	CI

Chart Cullinan Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.3 USD

Average target price

28.71 USD

Spread / Average Target

+13.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CULLINAN THERAPEUTICS, INC.	+148.28%	1.09B
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research